Olema Pharmaceuticals, Inc.
OLMA
$5.59
-$0.17-2.95%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -142.30M | -128.89M | -129.47M | -122.68M | -109.63M |
| Total Depreciation and Amortization | 471.00K | 433.00K | 393.00K | 365.00K | 360.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.74M | 15.29M | 15.57M | 12.98M | 12.31M |
| Change in Net Operating Assets | -73.00K | -11.66M | 9.16M | 12.79M | 4.68M |
| Cash from Operations | -127.16M | -124.83M | -104.35M | -96.54M | -92.27M |
| Capital Expenditure | 0.00 | -6.00K | -159.00K | -159.00K | -159.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 14.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -79.35M | -118.46M | -93.37M | -9.86M | -81.23M |
| Cash from Investing | -79.35M | -118.47M | -93.53M | -10.02M | -81.37M |
| Total Debt Issued | 3.00M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 252.11M | 266.73M | 275.48M | 24.97M | 155.74M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -13.01M | -6.51M | -6.66M | 74.00K | -166.00K |
| Cash from Financing | 242.10M | 260.22M | 268.82M | 25.04M | 155.58M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 35.58M | 16.92M | 70.94M | -81.52M | -18.07M |